Sunday, January 18, 2026 5:55:07 PM
You are creating a nice sense of authority with this sophisticat speculation, but it remains exactly that... speculation. Yes there are new rules coming into play, but no, there is not a shred of evidence anywhere to support your notion that NWBO are going to take advantage of these new rules both immediately and in secrecy!
Confidential pre-filing does not supersede or bypass the required public notification period.
A secondary listing fast track under UKLR 14 has strict eligibility requirements including having a home listing on a regulated market. NWBOs OTC listing therefore disqualifies it from this option. The OTC is not considered a regulated market by the FCA.
Your XLOM claim is simply not true. Look at the actual history of these trades on the LSE website. Nothing is new, absolutely nothing has changed in volume or qty of trades.
Your claim about the 8K disclosure is also spurious because if the 2.6B shares were intended for a London listing, the Proxy Statement sent to shareholders in November 2025 would have legally been required to disclose a potential dual-listing as a reason for the increase to avoid misleading shareholders. It didn't.
Confidential pre-filing does not supersede or bypass the required public notification period.
A secondary listing fast track under UKLR 14 has strict eligibility requirements including having a home listing on a regulated market. NWBOs OTC listing therefore disqualifies it from this option. The OTC is not considered a regulated market by the FCA.
Your XLOM claim is simply not true. Look at the actual history of these trades on the LSE website. Nothing is new, absolutely nothing has changed in volume or qty of trades.
Your claim about the 8K disclosure is also spurious because if the 2.6B shares were intended for a London listing, the Proxy Statement sent to shareholders in November 2025 would have legally been required to disclose a potential dual-listing as a reason for the increase to avoid misleading shareholders. It didn't.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
